TAXONAB 100MG ING

About

TAXONAB is an antineoplastic agent belonging to the taxane class, specifically a nanoparticle albumin-bound formulation of paclitaxel. This formulation allows for higher concentrations of paclitaxel to be delivered to tumor sites while potentially reducing the incidence of hypersensitivity reactions associated with solvent-based paclitaxel. It exerts its cytotoxic effects by promoting the assembly of microtubules from tubulin dimers and stabilizing them, preventing depolymerization. This leads to the inhibition of normal dynamic reorganization of the microtubule network, which is essential for vital interphase and mitotic cellular functions. Consequently, it arrests cells in the G2/M phase of the cell cycle and induces apoptosis, thereby inhibiting tumor growth and proliferation.

It is designed to improve drug delivery and efficacy in various solid tumors. The albumin component facilitates transport across endothelial cells, enhancing its accumulation within tumor tissues. Its mechanism disrupts the cell's internal scaffolding, preventing cell division and ultimately leading to cancer cell death. This targeted approach makes it a valuable option in oncology, often used when other treatments have failed or in specific advanced disease settings.

Uses

• Treatment of metastatic breast cancer after failure of combination chemotherapy.
• First-line treatment of locally advanced or metastatic non-small cell lung cancer.
• Treatment of metastatic adenocarcinoma of the pancreas.
• Used in combination with other agents for various solid tumors.

Directions For Use

Administered intravenously by a healthcare professional. Dosage and infusion rate are determined by the patient's condition and specific cancer type.

Benefits

• Effective against various solid tumors.
• Improved tumor drug delivery compared to conventional paclitaxel.
• Reduced risk of hypersensitivity reactions.
• Potential for higher dose intensity.
• May improve progression-free survival in certain cancers.
• Offers a treatment option for advanced or refractory cancers.

Side Effects

• Peripheral neuropathy
• Myelosuppression (neutropenia, anemia, thrombocytopenia)
• Fatigue/Asthenia
• Nausea and vomiting
• Diarrhea
• Alopecia (hair loss)
• Arthralgia/Myalgia
• Edema
• Hypersensitivity reactions
• Infections
• Mucositis
• Liver enzyme elevations

Safety Measures

• Alcohol - Avoid alcohol during treatment as it may exacerbate side effects like liver toxicity or gastrointestinal upset.
• Pregnancy - Contraindicated in pregnancy due to potential for fetal harm. Effective contraception is required for both male and female patients.
• Breastfeeding - Breastfeeding is not recommended during treatment and for a period after the last dose due to potential harm to the infant.
• Liver - Use with caution in patients with hepatic impairment; dose adjustments may be necessary. Monitor liver function closely.
• Kidney - Use with caution in patients with renal impairment; dose adjustments may be necessary. Monitor kidney function.
• Lung - Monitor for signs of pneumonitis or interstitial lung disease, especially in patients with pre-existing lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.